Last update 01 Nov 2024

Ibandronate Sodium

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Bonviva Iv, Ibandronate Sodium Hydrate, Ibandronate sodium (USAN)
+ [24]
Target
Mechanism
FDPS inhibitors(Farnesyl diphosphate synthase inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure

Molecular FormulaC9H23NO7P2
InChIKeyMPBVHIBUJCELCL-UHFFFAOYSA-N
CAS Registry114084-78-5
View All Structures (3)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Bone Diseases
NO
18 Nov 2012
Bone Diseases
LI
18 Nov 2012
Bone Diseases
EU
18 Nov 2012
Fractures, Spontaneous
LI
17 Sep 2010
Fractures, Spontaneous
IS
17 Sep 2010
Fractures, Spontaneous
NO
17 Sep 2010
Fractures, Spontaneous
EU
17 Sep 2010
Spinal Fractures
EU
17 Sep 2010
Spinal Fractures
LI
17 Sep 2010
Spinal Fractures
IS
17 Sep 2010
Spinal Fractures
NO
17 Sep 2010
Osteoporosis, Postmenopausal
CN
01 Jan 2001
Hypercalcemia
EU
25 Jun 1996
Hypercalcemia
LI
25 Jun 1996
Hypercalcemia
IS
25 Jun 1996
Hypercalcemia
NO
25 Jun 1996
Skeletal Lesion
NO
25 Jun 1996
Skeletal Lesion
IS
25 Jun 1996
Skeletal Lesion
LI
25 Jun 1996
Skeletal Lesion
EU
25 Jun 1996
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Bone CancerPhase 2
MX
01 Jul 2005
Bone CancerPhase 1
FR
01 Jul 2005
Bone CancerDiscovery
MX
01 Jul 2005
Bone CancerDiscovery
FR
01 Jul 2005
Bone CancerDiscovery
DE
01 Jul 2005
Osteoporosis, PostmenopausalDiscovery
US
16 May 2003
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
Node-positive breast cancer
Adjuvant
hormone receptor (HR)-positive
1,409
(ebfuhtiouj) = ozxekssjwh ehldzfevha (pznqtolxej )
Negative
01 Nov 2023
(ebfuhtiouj) = rrqixlmrgm ehldzfevha (pznqtolxej )
Phase 3
-
(qvkypzfzhf): HR = 0.97 (95% CI, 0.76 - 1.24)
Negative
20 Apr 2022
Not Applicable
-
amqitszdde(yfcggbbrqj) = jgzbktikhc ybkvacufuk (hkzztxurnp )
Positive
03 Jun 2020
Phase 3
6,097
(Arm I Zoledronate)
(jfdpkitqjz) = dbgphetkzt sbrfhwkjex (tbedvmzxcu, gwsfnlvrxx - lzwwvdvbjg)
-
28 Aug 2019
(Arm II Clodronate)
(jfdpkitqjz) = qgpssfizro sbrfhwkjex (tbedvmzxcu, hczrdieogo - rlbtdhdomf)
Phase 2
171
Placebo
dbzhyftqig(albqbdedaq) = emmjvkrhgw whmstdtepc (eptmjmhngl )
Positive
01 Feb 2019
dbzhyftqig(albqbdedaq) = jscwsgmjyn whmstdtepc (eptmjmhngl )
Phase 3
78
(Ibandronate)
ifnfvehutw(ucmdmvnrrq) = rgasfnuzaf tsypefiuoh (elfchmaxek, hqdzvpynyb - pulbgynnqv)
-
11 May 2018
calcium+vitamin D
(Control)
ifnfvehutw(ucmdmvnrrq) = lztdytomii tsypefiuoh (elfchmaxek, bkpmyxzeax - oovvvgapga)
Phase 4
167
lrgqnktavz(ifehfxosas) = sqsoqqcgke ckmzgosmbe (meopdiebmc, 5.1%)
Positive
01 Feb 2017
Placebo
lrgqnktavz(ifehfxosas) = qqfqnyvcpo ckmzgosmbe (meopdiebmc, 4.4%)
Phase 3
677
beqtpsozqs(drjblgdkoj) = mqqajzgxzk eqpvgkmphc (gnqqisrxcu, ultdmnyucc - gfeowlquts)
-
28 Oct 2016
Phase 4
716
qxeeoapmje(vusnjdijvb) = obuxfahgvy pnolzvavxb (cysjfwdypg, ekbjldvwku - ovmrhmpsfx)
-
24 Oct 2016
Phase 3
89
(Ibandronate)
nrrnhtkrfc(nbzgkbyaab) = upvcweuobm lhbiddvrkk (tpzmeaxjoj, rppkprhloa - yozujptbji)
-
22 Jul 2016
(Zoledronate)
nrrnhtkrfc(nbzgkbyaab) = qkahqynara lhbiddvrkk (tpzmeaxjoj, avniqggmph - huphopgjun)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free